EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB

What it is

EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB is how the CMS NADAC file names this product. The FDA NDC Directory lists it as emtricitabine and tenofovir disoproxil fumarate.

FDA gives its dosage form as tablet, film coated and its route as oral.

FDA lists 10 labelers (the companies named on the label) for its NDCs, among them Teva Pharmaceuticals USA, Inc., Major Pharmaceuticals and NorthStar RxLLC.

FDA lists it under 2 Established Pharmacologic Classes: Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor and Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor.

The NADAC file of 2026-10-14 prices it under 10 NDCs (National Drug Codes).

NADAC classes it as a generic drug (rate-setting class G), and does not mark it as sold over the counter.

What pharmacies pay

Pharmacies pay $15.87 for 30 tablets (30 × $0.52902 per EA, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.

NADAC’s explanation code for it: 1, calculated from the most recently completed pharmacy survey.

What NADAC measures · Why 30 tablets · NADAC explanation codes

The 10 labelers

Other strengths, forms and brands

2 other products in the NADAC file share the FDA nonproprietary name emtricitabine and tenofovir disoproxil fumarate with EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB.

Part D is one average per brand and generic name, over every strength and form.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-04-22, 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18

Compared with its class

The middle of its 10 NDCs’ NADAC prices is $0.52902 per EA filed.

Of the 28 other products in FDA’s Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor class priced per EA, 24 have a higher middle NADAC price and 4 a lower one. The one in the middle is VEMLIDY 25 MG TABLET, at $51.98384 per EA filed (eff. 2026-09-23).

Of the 28 other products in FDA’s Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor class priced per EA, 25 have a higher middle NADAC price and 3 a lower one. The one in the middle is VEMLIDY 25 MG TABLET, at $51.98384 per EA filed (eff. 2026-09-23).

Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

How the class comparison works

What Medicare paid

We don’t know yet; the card above says why.

Which Medicare figure OpenBill compares · How Part D is matched · How Part B is matched

What to ask at the counter

None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.

• What is your cash price for 30 tablets? Is it lower than what I would pay through my insurance?
• These are questions about price, not medical advice. Do not change or stop a medicine without talking to your prescriber or pharmacist.